In addition, cardiac death, myocardial infarction [MI] and stent thrombosis was also numerically less (although did not reach statistical significance). 3 Subsequently, the SPIRIT-III, a randomized controlled, multi-centric study, comparing Xience V with Taxus stent also revealed that at the end of 2 years, Xience V showed superior results; target vessel failure [TVF] showed a 32% reduction (10.7 vs. 15.4%, hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.48–0.98; p = 0.04) and a 45% reduction in major adverse cardiac events [MACE] (7.3 vs. 12.8%, HR 0.55, 95% CI 0.36–0.83; p = 0.004). 4 SPIRIT IV randomized 3690 patients to receive the Xience V or Taxus stent.
1
—
—